Search clinical trials for: BG9924

Total 21 results

Biogen

Terminated

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (RESPOND-EXT)

Rheumatoid Arthritis

Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russian Federation, United Kingdom
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Biogen

Completed

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, United States
Biogen

Terminated

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Biogen

Terminated

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Rheumatoid Arthritis

United States, Belgium, Canada, United Kingdom
Novo Nordisk A/S

Completed

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BerGenBio ASA

Terminated

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Brain and Central Nervous System Tumors

United States
Biogen

Completed

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (RESPOND)

Rheumatoid Arthritis

Argentina, Mexico, Romania, Brazil, Hungary, Poland, Russian Federation, United Kingdom
Bayer

Completed

To Evaluate Clinical Outcome and Injection Compliance of Scilin (SEAS)

Diabetes Mellitus, Type 2

China
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway
Eli Lilly and Company

Completed

A Study to Compare Two Forms of LY2608204 in Healthy People

Healthy Volunteers

Singapore
Haukeland University Hospital
BerGenBio ASA

Active, not recruiting

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Melanoma

Norway
University of Texas Southwestern Medical Center
Texas Tech University Health Sciences Center; BerGenBio ASA

Completed

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Non-Small Cell Lung Carcinoma

United States
BerGenBio ASA

Completed

A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
BerGenBio ASA
Merck Sharp & Dohme LLC

Completed

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Lung Cancer Metastatic | Adenocarcinoma of Lung | NSCLC Stage IV

United States, Spain, United Kingdom, Norway
Biogen

Completed

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency (TRIDENT-1)

Renal Insufficiency | Congestive Heart Failure

Israel, Italy, United States, Finland, Canada, Australia, France, Netherlands, Poland, Bulgaria, Russian Federation, India, Brazil, Sweden, Romania, Czechia, Argentina, Germany
BerGenBio ASA

Active, not recruiting

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Germany, Italy, Norway
Biogen

Terminated

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency (POSEIDON)

Heart Failure | Renal Insufficiency

United States
University of Leicester
Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaborators

Active, not recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST)

Mesothelioma, Malignant

United Kingdom

Search clinical trials for: BG9924

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations